MCOV B Stock Overview
Provides healthcare and diagnostic services in Poland, Sweden, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Medicover AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 187.80 |
| 52 Week High | SEK 206.50 |
| 52 Week Low | SEK 118.30 |
| Beta | 1.47 |
| 11 Month Change | 0.75% |
| 3 Month Change | -7.94% |
| 1 Year Change | 19.01% |
| 33 Year Change | -33.17% |
| 5 Year Change | 125.45% |
| Change since IPO | 186.72% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects
Apr 22
Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings
Apr 04Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet
Mar 05Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price
Feb 11Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture
Dec 20Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?
Dec 02Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business
Sep 12Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet
Aug 21Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?
Jun 12Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends
May 27Is Medicover (STO:MCOV B) Using Too Much Debt?
May 12Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes
Feb 16Is Medicover (STO:MCOV B) Using Too Much Debt?
Jan 30Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?
Dec 30Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)
Dec 17Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger
Oct 30Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?
Oct 16Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?
Sep 09Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)
Jul 25Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet
Jul 12Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)
Jun 13At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?
May 29With EPS Growth And More, Medicover (STO:MCOV B) Is Interesting
Apr 20Medicover (STO:MCOV B) Could Easily Take On More Debt
Apr 08Shareholder Returns
| MCOV B | SE Healthcare | SE Market | |
|---|---|---|---|
| 7D | 3.2% | 0.5% | 1.0% |
| 1Y | 19.0% | 36.3% | 20.6% |
Return vs Industry: MCOV B underperformed the Swedish Healthcare industry which returned 36.3% over the past year.
Return vs Market: MCOV B underperformed the Swedish Market which returned 20.6% over the past year.
Price Volatility
| MCOV B volatility | |
|---|---|
| MCOV B Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MCOV B has not had significant price volatility in the past 3 months.
Volatility Over Time: MCOV B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 45,000 | Fredrik Rågmark | www.medicover.com |
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company’s Healthcare services includes service outpatient and inpatient care; dental services; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness services; hospital care; and preventive care. Its Diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology.
Medicover AB (publ) Fundamentals Summary
| MCOV B fundamental statistics | |
|---|---|
| Market cap | SEK 28.20b |
| Earnings (TTM) | SEK 262.13m |
| Revenue (TTM) | SEK 21.68b |
107.6x
P/E Ratio1.3x
P/S RatioIs MCOV B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCOV B income statement (TTM) | |
|---|---|
| Revenue | €1.91b |
| Cost of Revenue | €1.52b |
| Gross Profit | €394.70m |
| Other Expenses | €371.60m |
| Earnings | €23.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 20.66% |
| Net Profit Margin | 1.21% |
| Debt/Equity Ratio | 124.4% |
How did MCOV B perform over the long term?
See historical performance and comparison